IL6R and COVID-19: Although a previous report showed largely neutral effects of tocilizumab compared to placebo in hospitalised COVID-19 patients (Stone et al., 2020), two recent trials (REMAP-CAP Anthony C and Paul R, 2021 and RECOVERY RECOVERY Collaborative Group, 2021) with a longer follow-up period showed beneficial effects on survival at 90 days, consistent with the prediction of a protective effect using the tocilizumab-mimicking IL-6R genetic instrument in the present study and the previous report.